Pfizer Lays Out A Growth Plan To Offset $17bn In Coming Exclusivity Losses
Executive Summary
Management presented a strategy for establishing new blockbuster brands in migraine, RSV, inflammatory bowel disease, cancer and diabetes/obesity during an investor day.
You may also be interested in...
The Biggest M&A Announcements Of 2023 Show Deals Are Getting Bigger
M&A activity in 2023 began with March’s $43bn mega-deal for Seagen, but only one eight-figure takeout has occurred since. Still, the values are higher overall than seen in 2022 and might indicate a gradual return to larger deals.
As Time Ticks, Industry Edges Closer To The Big Patent Cliff
Big pharma manufacturers are approaching a period that will be marked by the loss of exclusivity of many big-selling brands. All of the players are looking for ways to navigate the loss of revenues.
Pfizer Shakes Up R&D Leadership, Streamlining Oncology Ahead Of Seagen Merger
Chief development officer William Pao will depart the company in a sudden transition after being recruited from Roche. Pfizer insiders Chris Boshoff and Mikael Dolsten will fill the roles.